0001127602-20-021823.txt : 20200720
0001127602-20-021823.hdr.sgml : 20200720
20200720165312
ACCESSION NUMBER: 0001127602-20-021823
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200717
FILED AS OF DATE: 20200720
DATE AS OF CHANGE: 20200720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gerberding Julie L.
CENTRAL INDEX KEY: 0001628884
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06571
FILM NUMBER: 201036855
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Merck & Co., Inc.
CENTRAL INDEX KEY: 0000310158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 221918501
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
BUSINESS PHONE: 908-740-4000
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
FORMER COMPANY:
FORMER CONFORMED NAME: Merck & Co. Inc.
DATE OF NAME CHANGE: 20091103
FORMER COMPANY:
FORMER CONFORMED NAME: SCHERING PLOUGH CORP
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-07-17
0000310158
Merck & Co., Inc.
MRK
0001628884
Gerberding Julie L.
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH
NJ
07033
1
EVP Strat Comm, GI Pub Policy
Common Stock
2020-07-17
4
M
0
18111
0
A
62862.138
D
Common Stock
2020-07-17
4
S
0
18111
80.00
D
44751.138
D
Common Stock
2020-07-17
4
S
0
18174
80.0097
D
26577.138
D
Stock Option (Right to Buy)
54.68
2020-07-17
4
M
0
18111
0
D
2017-05-10
2026-05-09
Common Stock
18111
0
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Holdings include shares acquired in dividend reinvestment transactions.
The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Faye C. Brown as Attorney-in-Fact for Julie L. Gerberding
2020-07-20